ADCendo

Denmark
Copenhagen, Capital Region, Denmark

Company profile

ADCendo company profile

ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0+
Founded
2017-01-01, Year

Headquarters

Country code
DK
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
6
Total equity funding
$248.1M
Last funding
Series B / $135M / 2024-11-25
Last equity funding
Series B / $135M
Investors
14
Lead investors
6
Founders
4
Articles
45

Founders and investors

Founders

Christoffer NielsenHenrik StageLars H. EngelholmNiels Behrendt

Lead investors

Dawn BiopharmaNovo HoldingsNovo Nordisk FoundationPontifaxTCG CrossoverYsios Capital

Investors

Novo HoldingsOrbiMedRA Capital ManagementTCG CrossoverTPG